Material suplementario

Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardíaca aguda reciente

aServicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, España
bLaboratorio de Análisis Clínicos, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, España
cServicio de Cardiología, Hospital Universitario Los Arcos del Mar Menor, San Javier, Murcia, España
dCentre for Cardiovascular Sciences, City Hospital, University of Birmingham, Birmingham, Reino Unido
eServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Murcia, España
Table 1 of the supplementary material

Renal Function Variation According to Hypothetical Need for Dosage Adjustment of Each Nonvitamin K Oral Anticoagulants

<table>
<thead>
<tr>
<th></th>
<th>Dabigatran</th>
<th>Rivaroxaban</th>
<th>Apixaban</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (n = 90)</td>
<td>Yes (n = 72)</td>
<td>P</td>
</tr>
<tr>
<td>CrCl relative variation, %</td>
<td>23 (14)</td>
<td>55 (55)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>CrCl absolute variation, L/min</td>
<td>16 (14)</td>
<td>24 (21)</td>
<td>.004</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± standard deviation
**Table 2 of the supplementary material**

Percentage of Patients That Would Have Needed at Least 1 Hypothetical Dosage Adjustment of Each Nonvitamin K Oral Anticoagulant According to Creatinine Clearance at Hospital Discharge

<table>
<thead>
<tr>
<th>Creatinine clearance at discharge</th>
<th>&lt;15 mL/min (n = 1)</th>
<th>15-24.9 mL/min (n = 9)</th>
<th>25-34.9 mL/min (n = 20)</th>
<th>35-44.9 mL/min (n = 26)</th>
<th>45-54.9 mL/min (n = 22)</th>
<th>55-64.9 mL/min (n = 26)</th>
<th>65-74.9 mL/min (n = 19)</th>
<th>≥75 mL/min (n = 39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dabigatran</td>
<td>1 (100%)</td>
<td>2 (22%)</td>
<td>14 (70%)</td>
<td>16 (62%)</td>
<td>16 (73%)</td>
<td>12 (46%)</td>
<td>8 (42%)</td>
<td>3 (8%)</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>1 (100%)</td>
<td>4 (44%)</td>
<td>3 (15%)</td>
<td>11 (42%)</td>
<td>15 (69%)</td>
<td>12 (46%)</td>
<td>8 (42%)</td>
<td>3 (8%)</td>
</tr>
<tr>
<td>Apixaban</td>
<td>1 (100%)</td>
<td>5 (56%)</td>
<td>15 (75%)</td>
<td>13 (50%)</td>
<td>6 (27%)</td>
<td>4 (15%)</td>
<td>2 (11%)</td>
<td>1 (3%)</td>
</tr>
</tbody>
</table>
Figure 1 of the supplementary material. Flow diagram for participants included in the study.

Patients discharged from our hospital with a concomitant diagnosis of atrial fibrillation and acute decompensated heart failure between 1st January 2008 and 31st December 2011 (n = 253)

Patients with non-renal contraindication to Non-Vitamin K oral anticoagulants:
- Prosthetic mechanical heart valve (n = 27)
- Moderate-severe mitral stenosis (n = 12)
- Hypertrophic cardiomyopathy (n = 7)
- Age <18 years (n = 2)
- Other (n = 10)

On kidney replacement therapy (n = 3)

Patients in which creatinine determinations during 6 months of follow-up were analyzed (n = 192)

Patients without any serum creatinine measurement during follow-up (n = 30)

Final study population (n = 162)